<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPL) are a common cause of acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>, termed <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS, Huges syndrome) </plain></SENT>
<SENT sid="1" pm="."><plain>Catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (CAPS, Asherson's syndrome) is an unusual form of APS characterized with multi-organ failure and high mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Fortunately, CAPS accounts for less than 1% of APS cases </plain></SENT>
<SENT sid="3" pm="."><plain>The recurrence rate is low with a stable clinical course if these patients are treated with adequate anticoagulation therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Due to the rarity of the condition, an international registry of CAPS patients was created in 2000 supported by the European Forum on <z:hpo ids='HP_0003613'>Antiphospholipid Antibodies</z:hpo> held in Taormina, Italy at the Tenth International Congress on aPL </plain></SENT>
<SENT sid="5" pm="."><plain>The objective of our study is to describe characteristics of 12 Serbian patients with CAPS included in the international CAPS registry </plain></SENT>
</text></document>